TheraRadar
← Back
Data updated: Jun 28, 2026

ARGENX BV

Biotech
NeurologyOphthalmologyMetabolic Execution: Fair

ARGENX BV is a biotechnology company focused on Neurology, Ophthalmology, Metabolic. Key products include VYVGART.

2021
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

FDA Novel Drug Designations

(2021)
1 Novel 1 First-in-Class 1 Orphan 1 Fast Track
See 1 novel approval →
2021 VYVGART (EFGARTIGIMOD ALFA) First-in-Class · Orphan · Fast Track

ARGENX BV at a Glance

  • Fast trial execution (23 months median completion)

ARGENX BV's Key Drugs

ARGENX BV's core commercial portfolio centers on VYVGART HYTRULO, VYVGART, spanning Neurology and Ophthalmology — its most strategically important drugs approved in the last 15 years.

VYVGART HYTRULO
Immunology

Myasthenia Gravis

FcRn Approved 2023
VYVGART
Immunology

Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

FcRn Approved 2021

ARGENX BV's Recent FDA Approvals

New NDA/BLA approvals for ARGENX BV over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ARGENX BV's Therapeutic Areas

ARGENX BV's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Ophthalmology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 54%
1 drugs Phase 3: 3 Phase 2: 5 Phase 1: 2
Ophthalmology 21%
0 drugs Phase 3: 3
Metabolic 14%
0 drugs Phase 3: 2
Immunology 7%
0 drugs Phase 2: 2
Oncology 4%
0 drugs Phase 1: 2

ARGENX BV's Top Competitors

ARGENX BV's closest competitors by therapeutic-area and drug-target overlap include Roche, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Roche big-pharma
Oncology, Immunology, Neurology, Ophthalmology, Metabolic
AbbVie big-pharma
Immunology, Oncology, Neurology, Ophthalmology
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Neurology
Pfizer big-pharma
Oncology, Immunology, Neurology
Novartis big-pharma
Oncology, Ophthalmology, Immunology

ARGENX BV Pipeline Snapshot

ARGENX BV has 19 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 7 Phase 2 and 4 Phase 1.

8
Phase 3
7
Phase 2
4
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • VYVGART HYTRULO leads revenue
  • • 2 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 9/23 completed
  • • Speed: 23 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges